Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Results from an IFCC global survey on laboratory practices for the analysis of circulating tumor DNA.

Clinica chimica acta; international journal of clinical chemistry - 1 Jul 2023

Linder Mark W, Huggett Jim F, Baluchova Katarina, Capoluongo Ettore D, Payne Deborah A, Salinas Aldo Vacaflores, Haselmann Verena, Ashavaid Tester, Pan Shiyang, Ahmad-Nejad Parviz

Abstract excerpt

BACKGROUND: The clinical validity of ctDNA analysis as a diagnostic, prognostic and predictive biomarker has been demonstrated in many studies. The rapid spread of tests for the analysis of ctDNA raises questions regarding their standardization and quality assurance. The aim of this study was to provide a global overview of the test methods, laboratory procedures and quality assessment practices using ctDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Laboratories

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Reference Standards

Source

Identifiers

PMID: 37217114
DOI: 10.1016/j.cca.2023.117398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Results from an IFCC global survey on laboratory practices for the analysis of circulating tumor DNA.PMID 37217114Read ↗

Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.Semantic proximity Read ↗

Implementation of circulating tumour DNA multi-target mutation testing in plasma: a perspective from an external quality assessment providers' survey.Semantic proximity Read ↗

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA WorkshopSemantic proximity Read ↗

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewSemantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platformsSemantic proximity Read ↗

Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends.Semantic proximity Read ↗

ctDNA as a Cancer Biomarker: A Broad OverviewSemantic proximity Read ↗

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.Semantic proximity Read ↗

ctDNA as a cancer biomarker: A broad overview.Semantic proximity Read ↗

Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and StagesSemantic proximity Read ↗

Results of a worldwide External Quality Assessment of cfDNA testing in Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.